Tofacitinib did not show an inhibitory effect on RANKL-induced osteoclast formation or differentiation in inflammatory arthritis animal models.[30,31] In contrast, tofacitinib treatment markedly prevented bone erosion in Wistar rats with adjuvant-induced arthritis compared to rats with arthritis not receiving tofacitinib.[21] Conversely, the role of baricitinib in bone remodeling is not clearly identified in RA. Here, TNFSF11 is linked to rheumatoid arthritis.